Friday, 20 Apr 2018

You are here

Allopurinol Dose Escalation is Safe with Severe CKD

Hypertension, nephrolithiasis and chronic kidney disease (CKD) commonly associates with gout.  While there is a clear need to dose adjust NSAIDs and colchicine in those with CKD, there is some debate about the need to dose adjust when using allopurinol with CKD.

Stamp and coworkers from Auckland did a post-hoc analysis of a 24-month allopurinol dose escalation treat-to-target randomized controlled trial to study the effect of baseline kidney function on safety and efficacy of allopurinol dose escalation to achieve serum urate (SU) <6 mg/dl.

In a trial of 183 gout patients, patients were randomized to either immediate or delayed (by 12 months) allopurinol dose escalation until serum uric acid (SUA) was <6 mg/dl. The effect of baseline kidney function on urate lowering and adverse effects was investigated.

Regardless of baseline creatinine clearance (CrCL) (<30 ml/min;  ≥30 to <60 ml/min; or ≥60 ml/min), the percentage who achieved SUA <6 mg/dl at the final visit was similar, 64.3% vs. 76.4% vs. 75.0%, respectively (p = 0.65).

The mean allopurinol dose at month 24 was significantly lower in those with CrCL <30 ml/min as compared to those with CrCL ≥30 to <60 ml/min or CrCL ≥60 ml/min (250 mg; 365 mg; 460 mg/day, respectively (p < 0.001). Thus, higher doses were needed to achieve target SUA levels in those with normal function and lower doses were needed with renal impairment.

Adverse events (deaths, increased LFTs, change in renal function) were similar among groups.

Allopurinol dose escalation to target SU appears to be safe in people with severe CKD. 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Unmet Needs in Calcium Pyrophosphate Deposition Disease

Abhishek et al have written on the results of an international survey of crystal arthritis experts and identified the unmet needs  regarding calcium pyrophosphate crystal deposition (CPPD) - research, classification, diagnosis and management.

CPPD is a highly prevalent condition with a range of manifestations that may lead to pain, synovitis and joint damage, especially in the elderly.

FIELD Study: Fenofibrate Reduces Uric Acid and Gout Risk

Lancet reports the results of the FIELD (Fenofibrate Intervention and Event Lowering in Diabetes) study - where fenofibrate was shown to reduce uric acid by 20%, gout events by nearly 50% and may be useful in preventing gout in diabetes. 

In the study, 9795 adults (age 50–75 years) with type 2 diabetes were randomized to receive fenofibrate 200 mg per day or placebo and followed for up to 5 years.

Time to Rethink Gout as a Chronic Disease

The current issue of JAMA has a perspective article on Gout’s bad rap as dietary disease rather than the complex, chronic inflammatory disorder that is ineffectively treated in many. 

The author and experts interviewed believe that the pipeline of new drugs for gout will fuel the future of evidence-based care and more informed lifestyle instruction.

Does Dose Escalation Help in Gout?

Contrary to expectations, dose escalation of allopurinol among patients with gout did not improve survival, a 10-year observational study found.

CARES Study- More CV Deaths with Febuxostat

The CARES study was presented Monday at the American College of Cardiology meeting in Orlando and finds that while the rates of all major cardiovascular (CV) events were comparable between febuxostat or allopurinol, there were more CV deaths with febuxostat. (Citation source bit.ly/2HtUEaz)